ABL1 and acute lymphoblastic leukemia: Other study limitations, common to phase 2 trials in adult ALL, were a non-randomized design that precluded drawing definite conclusions on key aspects of risk-oriented therapy, the reliance on historical controls that cannot match the precision of a randomized comparison of treatment results, and the lack of recognition of novel, highly adverse subsets such as early thymic precursor ALL52, Ph-like (BCR-ABL1-like) ALL53, and others.